TrialsgrambetaRCTs are beautiful

Felzartamab AMR

2024

Felzartamab in Chronic Active Antibody-Mediated Rejection

In 22 kidney-transplant recipients with chronic active antibody-mediated rejection, felzartamab resolved rejection morphology more often than placebo.

Result

Resolution of morphologic antibody-mediated rejection at week 24 (key secondary/efficacy endpoint; the trial's primary outcome was the safety and side-effect profile of felzartamab)
Absolute difference
62 points
NNT
2
Effect estimate

difference6295% CI 19-100

Absolute difference and NNT are derived from the event rates.

Also reported: Resolution of AMR at wk 24: risk ratio 0.23 (95% CI 0.06 to 0.83). Recurrent AMR observed during follow-up.

Original publication
Subtopic
Antibody-mediated rejection
Design
Phase 2 RCT
Relevance
Supporting: context rather than must-know.
Source
Mayer KA, et al. N Engl J Med. 2024;391(2):122-132.doi 10.1056/NEJMoa2400763

Discussion & critique

First evidence-based option in chronic active AMR, but a very small sample; phase 3 is awaited.